Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Apr 01, 2023 2:51pm
106 Views
Post# 35373874

RE:RE:Paladin Labs' Revenue Guidance (2007-2012)

RE:RE:Paladin Labs' Revenue Guidance (2007-2012)In 2003, revenue was almost even, other than that seemed to have been decent growth every year. Operating cash flow was a different case though... years of positive growth, negative growth and zero growth.

Year Revenue Growth Op. Cash Flow Growth
1997                    830   -                  446  
1998                 6 023 626 %                 1 343 401 %
1999               11 201 86 %                 2 896 116 %
2000               12 607 13 %                 1 507 -48 %
2001               17 795 41 %                 5 154 242 %
2002               23 355 31 %                 8 634 68 %
2003               23 859 2 %                 5 446 -37 %
2004               28 017 17 %                 4 441 -18 %
2005               33 923 21 %               10 380 134 %
2006               48 357 43 %               13 286 28 %
2007               62 941 30 %               17 770 34 %
2008               82 744 31 %               25 152 42 %
2009             109 693 33 %               46 558 85 %
2010             127 989 17 %               68 240 47 %
2011             141 466 11 %               68 113 0 %
2012             153 873 9 %               69 603 2 %
<< Previous
Bullboard Posts
Next >>